Maxcyte (MXCT) Long-Term Deferred Tax (2024 - 2025)
Maxcyte's (MXCT) quarterly Long-Term Deferred Tax came in at $39.5 million in Q4 2025, up 2487.03% year-on-year from $1.5 million in Q4 2024, and up 2487.03% on a QoQ basis from $1.5 million in Q4 2024.
Maxcyte (MXCT) Long-Term Deferred Tax (2024 - 2025) Analysis & Trends
Maxcyte (MXCT) has 2 years of Long-Term Deferred Tax data on file, last reported at $39.5 million in Q4 2025.
- On a quarterly basis, Long-Term Deferred Tax rose 2487.03% year-over-year to $39.5 million in Q4 2025; TTM through Dec 2025 was $39.5 million, a 2487.03% increase from a year earlier, with the FY2025 full-year figure at $39.5 million, up 2487.03% from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $39.5 million, up from $1.5 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for MXCT reached as high as $39.5 million in Q4 2025 and fell as low as $1.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Maxcyte | 110.62 Mn | 110.62 Mn | 8.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.50 Mn |
| Dec 31, 2024 | 1.53 Mn |